Methylene blue is safe when used at approved doses under medical supervision, but it carries real risks for specific groups of people and interacts dangerously with common medications. The FDA approved it in 2016 for treating a blood condition called acquired methemoglobinemia, where red blood cells can’t deliver oxygen properly. Outside that narrow medical use, methylene blue has gained popularity as a supplement, and that’s where safety gets complicated.
Common Side Effects
At therapeutic doses, methylene blue causes a handful of predictable side effects that are mostly harmless. The most noticeable: your urine turns blue or green, sometimes for a day or more. Your skin can also take on a bluish tint temporarily. Beyond the color changes, nausea, diarrhea, dizziness, and headache are the most frequently reported effects. These generally don’t require medical attention and resolve on their own.
The cosmetic effects catch people off guard but aren’t dangerous. The blue discoloration of urine is simply the dye being filtered out by your kidneys, and it fades once the compound clears your system.
The Dangerous Interaction With Antidepressants
The most serious safety concern with methylene blue is its interaction with a wide range of psychiatric medications. Methylene blue is a potent, reversible inhibitor of the enzyme that breaks down serotonin in the brain. If you take it while also using a medication that raises serotonin levels, the combination can cause serotonin syndrome, a potentially life-threatening condition marked by agitation, confusion, rapid heart rate, high blood pressure, muscle rigidity, and seizures.
The FDA has issued a specific safety communication about this risk. The list of interacting medications is long and includes some of the most commonly prescribed drugs in the world:
- SSRIs such as sertraline (Zoloft), fluoxetine (Prozac), escitalopram (Lexapro), and citalopram (Celexa)
- SNRIs such as venlafaxine (Effexor) and duloxetine (Cymbalta)
- Tricyclic antidepressants such as amitriptyline and nortriptyline
- MAOIs such as phenelzine (Nardil) and selegiline (Emsam)
- Other psychiatric drugs including trazodone, buspirone (Buspar), bupropion (Wellbutrin), and mirtazapine (Remeron)
If you take any antidepressant, anti-anxiety medication, or mood stabilizer, this interaction is not theoretical. It is the single biggest safety red flag with methylene blue. Because many people exploring methylene blue as a supplement may also be on one of these medications, this overlap deserves serious attention before trying it.
G6PD Deficiency: A Genetic Deal-Breaker
People with G6PD deficiency, an inherited enzyme shortage affecting roughly 400 million people worldwide (most commonly men of African, Mediterranean, or Asian descent), should not take methylene blue. The compound works by relying on a biochemical pathway that requires this specific enzyme. Without it, methylene blue can’t do its job and instead triggers the destruction of red blood cells, a condition called hemolytic anemia.
This isn’t a mild side effect. Hemolytic anemia from methylene blue in someone with G6PD deficiency can be severe enough to require blood transfusions. Many people don’t know they carry this enzyme deficiency because it often causes no symptoms in everyday life. If you’ve never been tested and you’re considering methylene blue, a simple blood test can rule it out.
Dosing and the Safety Window
In clinical settings, methylene blue is given intravenously at 1 mg per kilogram of body weight. For a 70 kg (154 lb) person, that’s about 70 mg. If the first dose doesn’t resolve the problem, a second dose of the same amount can be given an hour later. Beyond two doses, clinicians move to alternative treatments rather than giving more.
This dosing ceiling matters because toxicity increases sharply at higher amounts. At doses above 7 mg/kg, methylene blue can paradoxically cause the very condition it treats (methemoglobinemia), along with chest pain, shortness of breath, and cardiovascular instability. The gap between therapeutic and toxic isn’t as wide as it is for many other compounds, which is one reason careful dosing matters.
Supplement products sold online typically offer much lower doses than clinical IV administration, but they come with their own problem: inconsistent purity. Methylene blue exists in industrial grades (used for staining in labs and aquariums) and pharmaceutical (USP) grade, which must meet strict purity standards. Industrial-grade products can contain heavy metals and other contaminants. If you’re purchasing methylene blue as a supplement, pharmaceutical-grade purity with third-party testing is the minimum standard worth accepting.
Pregnancy and Breastfeeding
Safety data during pregnancy is limited, and methylene blue is generally avoided in pregnant women. During breastfeeding, the picture is slightly more nuanced. An older study found that after IV administration to nursing mothers, no trace of methylene blue appeared in breast milk, likely because about 94% of the compound binds to proteins in the blood, making it difficult to cross into milk. Despite this, current labeling recommends discontinuing breastfeeding during treatment and for up to 8 days afterward, based on the drug’s 24-hour half-life. No safety data exists for oral methylene blue during breastfeeding.
Off-Label and Supplement Use
Much of the current interest in methylene blue comes from its off-label potential: cognitive enhancement, mitochondrial support, anti-aging effects. Early research in these areas exists but hasn’t translated into approved uses. The safety profile established in medical settings applies to controlled, pharmaceutical-grade doses given under supervision. When people self-administer methylene blue as a supplement, they’re operating outside that controlled framework, with variable product quality, no standardized dosing guidance, and no screening for the genetic conditions or drug interactions that make it dangerous.
Methylene blue is not inherently toxic at low doses for most healthy people who aren’t on serotonergic medications and don’t have G6PD deficiency. But “safe for most people in most circumstances” is a different statement than “safe,” and the consequences of falling into one of the risk categories are severe enough to warrant caution before treating it as a casual supplement.